BioCentury | Jun 26, 2020
Distillery Therapeutics

Promoting Golgi fragmentation to treat pancreatic cancer

...Next steps include investigating how to prevent the Golgi complex from secreting cancer-promoting chemokines. TARGET/MARKER/PATHWAY: Kruppel-like factor...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...E2F4) GBM Patient sample, mouse, cell line Inhibiting E2F4 could help treat GBM. McGill University Kruppel-like factor...
BioCentury | Jul 13, 2018
Clinical News

FDA lifts hold on Aptose blood cancer candidate

...oncogene homolog (MYC; c-Myc) dysregulation. APTO-253 is a small molecule optimized to increase expression of Kruppel-like factor...
...Biosciences Inc. (TSX:APS; NASDAQ:APTO), Mississauga, Ontario Product: APTO-253 (formerly LT-253, LOR-253) Business: Cancer Molecular target: Kruppel-like factor...
...and dose-limiting toxicities (DLTs); pharmacokinetics Status: Clinical hold lifted Milestone: NA Allison Johnson APTO-253, lor-253, lt-253 Aptose Biosciences Inc. Kruppel-like factor...
BioCentury | May 24, 2018
Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

...in Science Translational Medicine , researchers first found that increased expression of tumor suppressor genes Kruppel-like factor...
...correlated with expression of KLF17, CDH1 and CERS2. Jaime De Leon Nankai University Ceramide synthase 2 (CERS2) E-cadherin (CDH1) (CD324) KLF17 Kruppel-like factor...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

...kinase (IKK) 6 1 Interleukin-1 receptor-associated kinase 4 (IRAK4) 6 1 Interleukin-17F (IL-17F) 4 1 Kruppel-like factor...
BioCentury | Feb 3, 2017
Clinical News

APTO-253: Development delayed

...Inc. (TSX:APS; NASDAQ:APTO), Mississauga, Ontario Product: APTO-253 (formerly LT-253 , LOR-253) Business: Cancer Molecular target: Kruppel-like factor...
...tolerated dose (MTD) and dose-limiting toxicities (DLTs); pharmacokinetics Status: Development delayed Milestone: NA Julian Zhu APTO-253 Aptose Biosciences Inc. Kruppel-like factor...
BioCentury | Oct 27, 2016
Distillery Therapeutics

Neurology

...the effects of sustained or continuous KLF9 expression on memory in the aged mice. TARGET/MARKER/PATHWAY: Kruppel-like factor...
...2016 doi:10.1016/j.neuron.2016.08.009 CONTACT: Amar Sahay, Massachusetts General Hospital , Boston, Mass. email: asahay@mgh.harvard.edu Steven Hochhauser Massachusetts General Hospital Kruppel-like factor...
BioCentury | Oct 24, 2016
Clinical News

APTO-253: Phase Ib hold

...Cancer Molecular target: Kruppel-like factor 4 (KLF4) (EZF) Description: Small molecule optimized to increase expression of Kruppel-like factor...
BioCentury | Sep 19, 2016
Clinical News

APTO-253: Phase Ib hold

...Cancer Molecular target: Kruppel-like factor 4 (KLF4) (EZF) Description: Small molecule optimized to increase expression of Kruppel-like factor...
BioCentury | Apr 7, 2016
Distillery Therapeutics

Therapeutics: MAP kinase kinase kinase kinase 3 (MAP4K3; GLK); kruppel-like factor 2 (KLF2); kruppel-like factor 4 (KLF4; EZF)

...models. TARGET/MARKER/PATHWAY: MAP kinase kinase kinase kinase 3 (MAP4K3; GLK ); kruppel-like factor 2 (KLF2) ; kruppel-like factor...
Items per page:
1 - 10 of 26